Sort
4,870 grants matching “glp 1”
Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients
$300,000Robert Rodick · Vxbiosciences, Inc. · R42 · FY2023 · AI
Cat allergen-human Fc-gamma1 chimeric proteins to treat cat allergy
$300,000Nolan Sigal · Tunitas Therapeutics, Inc. · R43 · FY2010 · AI
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility
$299,999Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2017 · HD
Cardioprotection by inhibition of coagulation and inflammation in myocardial infarction
$299,999Tze-Chein Wun · Evas Therapeutics, Llc. · R43 · FY2018 · HL
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$299,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2022 · DK
Cell Based Therapy for Treatment of Traumatic Brain Injury
$299,999Robert William Mays · Athersys, Inc. · U44 · FY2012 · NS
Process development for manufacturing eCD4-Ig
$299,998Michael David Alpert · Emmune, Inc · R44 · FY2023 · AI
A Novel IL-35 Expressing Probiotic Platform for Inducing Allergen Specific Tolerance
$299,996Neil A Fanger · Virtici, Llc · R44 · FY2020 · AI
Safety and Efficacy of a Titratable External Shunt
$299,981Lucinda Camras · Camras Vision, Inc. · R44 · FY2016 · EY
Develop natural compound emodin as a novel therapy for calcific aortic valve disease
$299,953Mohamad Azhar · Acepre, Llc · R41 · FY2024 · HL
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease
$299,938Jay L Rothstein · Immunext, Inc. · R44 · FY2017 · AI
Development of Natural Product as Antimalarial Agent
$299,880Shuren Zhu · Radix Pharmaceuticals, Inc. · R43 · FY2007 · AI
Lung delivery of novel ACE2 variants for COVID-19
$299,842Jack Henkin · Angiotensin Therapeutics, Inc. · R43 · FY2022 · HL
A Novel Tolerance Therapeutic for Treating Graves' Disease
$299,840Neil A Fanger · Virtici, Llc · R44 · FY2018 · AI
Development of novel Amadorins for Diabetic Peripheral Neuropathy
$299,825Raja G Khalifah · Praetego, Inc. · R43 · FY2018 · DK
Role of GLP-1 in Normal and Abnormal Glucose Tolerance
$299,786David A. D'alessio · University Of Cincinnati · R01 · FY2006 · DK
Attenuating reperfusion injury with combined hypothermia and gradual reperfusion.
$299,761Thomas L Merrill · Focalcool, Llc · R43 · FY2013 · HL
Functional characterization of endocrine taste cells
$299,757Robert F Margolskee · Monell Chemical Senses Center · R01 · FY2013 · DC
Development of oral KCC2 enhancer drug for treatment of painful diabetic neuropathy
$299,756Shane Hegarty · Axonis Therapeutics, Inc. · R43 · FY2023 · DK
Development of an active site inhibitor of Fks1 as a broad spectrum antifungal agent
$299,697Terry Roemer · Prokaryotics, Inc. · R44 · FY2025 · AI
HCMV Therapeutic Antibody Safety Trial
$299,667Lawrence Michael Kauvar · Trellis Bioscience, Inc. · U44 · FY2020 · AI
Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein
$299,650Vira Bitko · Bluewillow Biologics, Inc. · R44 · FY2020 · AI
BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease
$299,576Josep Bassaganya-Riera · Biotherapeutics, Inc. · R44 · FY2018 · AI
HLS- Factor XII Inhibitor for Surface Initiated Thrombosis
$299,563Erik Ian Tucker · Aronora, Inc. · R44 · FY2016 · HL
Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS)
$299,561Frank Sciavolino · Thetis Pharmaceuticals, Llc · R44 · FY2021 · AI